Loo P S, Braunwalder A F, Lehmann J, Williams M, Sills M A
Research Department, CIBA-GEIGY Corporation, Summit, New Jersey 07901.
Mol Pharmacol. 1987 Dec;32(6):820-30.
Biochemical and electrophysiological studies have provided evidence that a complex comprising the N-methyl-D-aspartate (NMDA)-type excitatory amino acid (EAA) receptor and the phencyclidine (PCP) recognition site exists in mammalian brain. This complex, which has been compared to that established for the inhibitory amino acid, gamma-aminobutyric acid, and the benzodiazepine anxiolytic, diazepam, is sensitive to the effects of the divalent cation Mg2+, which has suggested the presence of a third, ion channel component. Using a radioreceptor assay for the PCP receptor, L-glutamate (L-Glu) produced a concentration-dependent increase in the binding of [3H]thienyl cyclohexylpiperazine ([3H]TCP) in well washed membranes from rat forebrain. The EAA produced a maximal increase in specific binding of 400%, with an EC50 value of 340 nM. The ability of L-Glu to enhance [3H]TCP binding was 10-fold more potent in the presence of 30 microM Mg2+, which inhibits NMDA-evoked responses in intact tissue preparations and produces a 50% increase in [3H]TCP binding on its own. Analysis of saturation curves indicated that the effect of both L-Glu and Mg2+ could be attributed to an increase in receptor affinity as well as increases in the proportion of a high affinity state of the PCP-binding site. Assessment of the effect of a number of EAAs on basal [3H]TCP binding (well washed membranes in the absence of either L-Glu or Mg2+) showed that the EAA recognition site involved in the effects of L-Glu was the NMDA subtype. Further studies examined a series of compounds thought to interact with either the NMDA or PCP components of the receptor complex under four binding conditions: basal, +Mg2+; +L-Glu; and +Mg2+/L-Glu. These results showed that dissociative anesthetics, such as dexoxadrol and PCP, as well as the novel anticonvulsant MK-801, selectively interact with the high affinity state of the PCP receptor. NMDA antagonists, such as CPP, were also found to inhibit binding to the high affinity state of the PCP receptor, although not as potently as the dissociative anesthetics. Interestingly, the NMDA antagonists did not inhibit any of the binding to the low affinity state of the receptor. The sigma ligands (+/-)-SKF 10,047 and haloperidol recognized two components of [3H]TCP binding only in the presence of L-Glu. The results of the present study are consistent with the finding that agonists of the NMDA receptor induce a high affinity state of the PCP receptor.
生物化学和电生理学研究已提供证据表明,在哺乳动物大脑中存在一种由N-甲基-D-天冬氨酸(NMDA)型兴奋性氨基酸(EAA)受体和苯环己哌啶(PCP)识别位点组成的复合物。这种复合物已被与为抑制性氨基酸γ-氨基丁酸和苯二氮䓬类抗焦虑药地西泮所确立的复合物相比较,它对二价阳离子Mg2+的作用敏感,这提示存在第三个离子通道成分。使用针对PCP受体的放射受体测定法,L-谷氨酸(L-Glu)在大鼠前脑充分洗涤的膜中使[3H]噻吩基环己基哌嗪([3H]TCP)的结合呈浓度依赖性增加。该EAA使特异性结合最大增加400%,EC50值为340 nM。在30 μM Mg2+存在下,L-Glu增强[3H]TCP结合的能力强10倍,Mg2+可抑制完整组织制剂中NMDA诱发的反应,并自身使[3H]TCP结合增加50%。饱和曲线分析表明,L-Glu和Mg2+的作用均可归因于受体亲和力的增加以及PCP结合位点高亲和力状态比例的增加。评估多种EAA对基础[3H]TCP结合(在不存在L-Glu或Mg2+的情况下充分洗涤的膜)的影响表明,参与L-Glu作用的EAA识别位点是NMDA亚型。进一步的研究在四种结合条件下检查了一系列被认为与受体复合物的NMDA或PCP成分相互作用的化合物:基础状态、+Mg2+;+L-Glu;以及+Mg2+/L-Glu。这些结果表明,分离性麻醉药,如右吗拉胺和PCP,以及新型抗惊厥药MK-801,选择性地与PCP受体的高亲和力状态相互作用。NMDA拮抗剂,如CPP,也被发现抑制与PCP受体高亲和力状态的结合,尽管效力不如分离性麻醉药。有趣的是,NMDA拮抗剂并不抑制与受体低亲和力状态的任何结合。σ配体(±)-SKF 10,047和氟哌啶醇仅在L-Glu存在时识别[3H]TCP结合的两个成分。本研究结果与NMDA受体激动剂诱导PCP受体高亲和力状态的发现一致。